Lupin
LUPIN · Pharma > Pharmaceuticals & Drugs · Chairman: Manju D Gupta · MD: Nilesh Gupta · Listing date: Sept. 11, 2001 · Employees: 18573 · Mumbai · http://www.lupin.com

Stock Price vs Company Growth
1d
0.3%
1w
0.8%
1m
5.0%
3m
7.8%
6m
5.6%
1y
0.7%
5y
18.2%
10y
2.1%
all
17.0%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 2,097 0.3%
1,900
2,106
Company Overview

Sales
24,751 Cr
Growth: 12.2%
Profit after Tax
4,325 Cr
Growth: 16.9%
Large Cap
95,792 Cr
P/E: 22.2x
Industry P/E: 33.3x
Fundamentals

Sales (Cr) ₹ 24,751
Growth 12.2%
EBITDA 27.3%
P/S 3.9x
Dividend 0.4%
P/E 22.2x
Book Value ₹ 436
PEG Ratio 1.8x
ROE 23.9%
P/B 4.8x
Shareholding Pattern

Institutions
Life Insurance Corporation Of India
6.99 %
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund
4.28 %
Government Pension Fund Global
1.21 %
Franklin India Focused Equity Fund
1.13 %
Icici Prudential Life Insurance Company Limited
1.13 %
Promoters
Lupin Investments Pvt Ltd
45.3 %
Manju D Gupta
0.85 %
Nilesh D Gupta
0.2 %
Anuja Gupta
0.16 %
Desh Bandhu Gupta Huf
0.14 %
Others
Rakesh Jhunjhunwala
1.6 %
Nps Trust - A/C Lic Pension Fund Sch-State Govt
1.48 %
Iepf
0.15 %
Increase    Decrease    No change
Company Profile Detailed

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in many markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S.
Investors (233)
Followers (56)